Teru Hideshima

A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma

Paul G. Richardson, Bart Barlogie, James R. Berenson et al. · New England Journal of Medicine · 2003 · 2.6K citations · Full text

Medicine, Pharmacology, Pharmacotherapy +10

The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells.

Teru Hideshima, Paul G. Richardson, D Chauhan et al. · PubMed · 2001 · 1.5K citations

Medicine, Oncology, Pharmacology +17

Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma

Faith E. Davies, Noopur Raje, Teru Hideshima et al. · Blood · 2001 · 905 citations

Medicine, Immunology, Oncology +12

NF-κB as a Therapeutic Target in Multiple Myeloma

Teru Hideshima, Dharminder Chauhan, Paul G. Richardson et al. · Journal of Biological Chemistry · 2002 · 892 citations · Full text

Life Sciences, Immunology, Pharmacology +16

Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma

Paul G. Richardson, Edie Weller, Sagar Lonial et al. · Blood · 2010 · 862 citations · Full text

Medicine, Pharmacology, Pharmacotherapy +13